Clinical trials: Neoplasms, Prostatic
Prostatic Neoplasms, Exercise
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC). The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased…
- Conditions
- Prostatic Neoplasms, Exercise, Soccer Training, Androgen Deprivation Therapy
- Trial name
- NCT01711892
- Testing
- Soccer training
- Where
- Denmark
- Volunteers
- 57 people
- Sponsor
- University of Copenhagen
Obesity, Prostate Cancer
Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy
The purpose of this study is to test how a weight management program affects substances in the blood called biomarkers that can show the presence or severity of cancer, compared to a standardized diet and exercise educational…
- Trial name
- WARRIOR (NCT03261271)
- Testing
- Weight Loss Program, Standardized educational flyer, Weight Maintenance Program
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Brain Metastasis, Bladder Cancer
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival.
- Conditions
- Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer
- Trial name
- NCT00587964
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02522715
- Testing
- Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostatic Neoplasms
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
This is a phase 1b study that follows a 3+3 dose escalation design and consists of a 21-day lead-in period of oral Polysaccharide Krestin (PSK)/placebo (study drug) alone followed by the addition to study drug of standard…
- Trial name
- NCT01685489
- Testing
- Docetaxel, PSK®
- Where
- United States
- Sponsor
- Bastyr University
Prostate Cancer
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Study of Radium Ra 223 dichloride with enzalutamide compared to enzalutamide alone in men with metastatic castration refractory prostate cancer
- Trial name
- NCT02199197
- Testing
- Radium Ra 223 Dichloride, Enzalutamide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Utah
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Prostate Cancer
Comparative Study of MRI and TU in Identifying Clinically Significant Prostate Cancer Among Ethnic Groups
This study is designed to compare the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Transrectal Ultrasound (TRUS) in detecting clinically significant prostate cancer, using histopathology (biopsy results) as the…
- Trial name
- NCT07048613
- Testing
- MRI (mpMRI)
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Superior University
Prostate Cancer
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Eligible patients will be enrolled in one of 4 cohorts where each cohort will allow 3 patients to be on study. Patients will receive both study drugs on escalated dosing schedule until the maximum of 400 mg PO BID is reached for…
- Trial name
- NCT00424385
- Testing
- Gleevec + Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer, Quality of Life
Prostate Cancer: Family Care for Patients and Spouses
The purpose of this study is to determine if a family-based intervention (The FOCUS Program) can improve the long-term quality of life and other psycho-social outcomes of men with prostate cancer and their spouses.
- Conditions
- Prostate Cancer, Quality of Life, Cancer Survivorship
- Trial name
- NCT00708968
- Testing
- FOCUS Program
- Where
- 3 sites in United States
- Volunteers
- 263 people
- Sponsor
- University of Michigan
Prostate Cancer
Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients
Objectives: The primary objective of this study is to determine whether bladder compliance is significantly lower in men who undergo prostatectomy for recurrence following primary radiation therapy than in men who undergo…
- Trial name
- NCT00901420
- Testing
- Urodynamics Test, Questionnaire
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically…
- Conditions
- Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
- Trial name
- RADVAN (NCT07477626)
- Testing
- Androgen Deprivation Therapy (ADT), radiotherapy
- Where
- 13 sites in China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-sen University
Neoplasms, Malignancies
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used.
- Trial name
- NCT02257476
- Testing
- Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer
A Study of a New PET Scanner in People With Cancer
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra.
- Conditions
- Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT07690917
- Testing
- Biograph Vision Quadra scanner, PET/CT
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 174 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Nutrition and Prostate Cancer
The purpose of this study is to assess the efficacy of Fermented Soy vs. placebo in 72 adults with localized prostate cancer prior to radical prostatectomy.
- Trial name
- NCT03532308
- Testing
- Fermented Soy
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Yale University
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer Metastatic, Bone Metastases
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included…
- Trial name
- ROTOR (NCT03223597)
- Testing
- Radium-223 dichloride
- Where
- 20 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.